ALPS Advisors
PVLA icon

ALPS Advisors’s Palvella Therapeutics PVLA Stock Holding History

ALPS Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
14,356
+3,224
+29% +$391K 0.01% 490
2026
Q1 		$1.39M Buy
11,132
+1,416
+15% +$148K 0.01% 485
2025
Q4 		$1.02M Buy
9,716
+4,230
+77% +$361K 0.01% 562
2025
Q3 		$344K Buy
+5,486
New +$245K ﹤0.01% 941

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ALPS Advisors's PVLA Position: Q2 2026 in Review

ALPS Advisors increased its Palvella Therapeutics (PVLA) stake by 29% in Q2 2026, buying an estimated $391K and bringing the position to 14,356 shares worth $2.19M. The position accounts for 0.01% of the portfolio, ranked #490.

ALPS Advisors first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • ALPS Advisors held 14,356 shares of Palvella Therapeutics worth $2.19M as of Q2 2026.
  • ALPS Advisors bought 3,224 Palvella Therapeutics shares in Q2 2026, an estimated $391K.
  • Palvella Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #490 holding.
  • ALPS Advisors first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.